JP2010500993A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500993A5
JP2010500993A5 JP2009524665A JP2009524665A JP2010500993A5 JP 2010500993 A5 JP2010500993 A5 JP 2010500993A5 JP 2009524665 A JP2009524665 A JP 2009524665A JP 2009524665 A JP2009524665 A JP 2009524665A JP 2010500993 A5 JP2010500993 A5 JP 2010500993A5
Authority
JP
Japan
Prior art keywords
optionally substituted
triazole
mercapto
phenyl
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009524665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500993A (ja
JP5480623B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017996 external-priority patent/WO2008021364A2/en
Publication of JP2010500993A publication Critical patent/JP2010500993A/ja
Publication of JP2010500993A5 publication Critical patent/JP2010500993A5/ja
Application granted granted Critical
Publication of JP5480623B2 publication Critical patent/JP5480623B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009524665A 2006-08-17 2007-08-14 Hsp90活性を調節するトリアゾール化合物 Expired - Fee Related JP5480623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83830606P 2006-08-17 2006-08-17
US60/838,306 2006-08-17
PCT/US2007/017996 WO2008021364A2 (en) 2006-08-17 2007-08-14 Triazole compounds that modulate hsp90 activity

Publications (3)

Publication Number Publication Date
JP2010500993A JP2010500993A (ja) 2010-01-14
JP2010500993A5 true JP2010500993A5 (enExample) 2010-10-21
JP5480623B2 JP5480623B2 (ja) 2014-04-23

Family

ID=38924466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524665A Expired - Fee Related JP5480623B2 (ja) 2006-08-17 2007-08-14 Hsp90活性を調節するトリアゾール化合物

Country Status (6)

Country Link
US (1) US8188075B2 (enExample)
EP (1) EP2054059A2 (enExample)
JP (1) JP5480623B2 (enExample)
AU (1) AU2007284537B2 (enExample)
CA (1) CA2659425C (enExample)
WO (1) WO2008021364A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140006070A (ko) 2004-11-18 2014-01-15 신타 파마슈티칼스 코프. Hsp90 활성을 조절하는 트리아졸 화합물
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
CA2653217A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
US8063083B2 (en) 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2035396B1 (en) 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2008051416A2 (en) * 2006-10-19 2008-05-02 Synta Pharmaceuticals Corp. Compounds that inhibit the activity of hsp90 for treating infections
CA2677481C (en) * 2007-02-08 2015-07-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2008153730A2 (en) * 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
US8450500B2 (en) 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
WO2009158026A1 (en) 2008-06-27 2009-12-30 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate hsp90 activity
ES2415234T3 (es) 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
WO2010017545A2 (en) 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US20130156755A1 (en) * 2010-04-19 2013-06-20 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
AU2012280931A1 (en) 2011-07-07 2014-02-27 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とhsp90阻害剤の組合せ療法
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
SG11201408679XA (en) 2012-06-26 2015-01-29 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN113874015B (zh) 2018-12-21 2024-05-24 细胞基因公司 Ripk2的噻吩并吡啶抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615637A1 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
AU2005327921A1 (en) * 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
KR20140006070A (ko) 2004-11-18 2014-01-15 신타 파마슈티칼스 코프. Hsp90 활성을 조절하는 트리아졸 화합물
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
RU2007137133A (ru) 2005-03-09 2009-04-20 Ниппон Каяку Кабусики Кайся (Jp) Новый ингибитор hsp90
CA2618628C (en) * 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102006023337A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
WO2007139952A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for the preparation of triazole compounds with hsp90 modulating activity
US8063083B2 (en) 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
CA2653217A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
EP2035396B1 (en) * 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity

Similar Documents

Publication Publication Date Title
JP2010500993A5 (enExample)
JP2008520702A5 (enExample)
JP2009538320A5 (enExample)
JP2009538322A5 (enExample)
JP2009538321A5 (enExample)
AU2007267843B2 (en) Method for treating proliferative disorders associated with protooncogene products
US7767665B2 (en) 1,3-benzothiazinone derivatives and use thereof
JP2013508378A5 (enExample)
HRP20130095T1 (hr) Spojevi triazola koji moduliraju aktivnost hsp90
JP2010536753A5 (enExample)
JP2010518085A5 (enExample)
US6436966B1 (en) Adenosine A3 receptor antagonists
AU2012200157B2 (en) Method for treating proliferative disorders associated with protooncogene products
JP2020527560A5 (enExample)
RU2006126663A (ru) Полициклические средства для лечения респираторно-синцитиальных вирусных инфекций
ZA200305619B (en) Substituted triazole diamine derivatives as kinase inhibitors.
JP2014526500A5 (enExample)
CA2451678A1 (en) Azaindoles
CA2456817A1 (en) Alkyne-aryl-naphthyridin-4 (1h)-one derivatives as type iv phosphodiesterase inhibitor
RU2010119487A (ru) Пиримидилиндолиновое соединение
JP2013501749A5 (enExample)
CN102712649A (zh) 苯并咪唑衍生物及其药物组合物和应用
JP2010540602A5 (enExample)
AU2009259021A1 (en) 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
JPWO2021053555A5 (enExample)